Maraviroc: perspectives for use in antiretroviral-naive HIV-1-infected patients

Lymphoma Diagnosis and Plasma Epstein‐Barr Virus Load during Vicriviroc Therapy: Results of the AIDS Clinical Trials Group A5211

(2009) Athe M. N. Tsibris et al.   CLINICAL INFECTIOUS DISEASES

CXCR4-Using HIV Type 1 Variants Are More Commonly Found in Peripheral Blood Mononuclear Cell DNA Than in Plasma RNA

(2009) Chris Verhofstede et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Maraviroc: integration of a new antiretroviral drug class into clinical practice

(2008) L. Vandekerckhove et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Inferior Clinical Outcome of the CD4+Cell Count–Guided Antiretroviral Treatment Interruption Strategy in the SMART Study: Role of CD4+Cell Counts and HIV RNA Levels during Follow‐up

(2008)   JOURNAL OF INFECTIOUS DISEASES

Phase II Study of Vicriviroc versus Efavirenz (both with Zidovudine/Lamivudine) in Treatment‐Naive Subjects with HIV‐1 Infection

(2008) Raphael J. Landovitz et al.   JOURNAL OF INFECTIOUS DISEASES

Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration

(2008)   LANCET

Maraviroc for Previously Treated Patients with R5 HIV-1 Infection

(2008) Roy M. Gulick et al.   NEW ENGLAND JOURNAL OF MEDICINE